ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sparsentan

Also written as “Sparsentan”, “PS433540” and “RE-021 (Sparsentan)”.

Its studies are mostly in Glomerulosclerosis, Focal Segmental · Glomerulonephritis, IGA · Hypertension · Proteinuria, led by 2 companies.

Drug pageSparsentan: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 9, 20259 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Travere Therapeutics72 open or runningphase 4since Oct 9, 2025Jun 4, 2012Mar 2027phase 4 · NCT07219121
Ligand Pharmaceuticalsits history only20 open or runningphase 2since Aug 29, 2007Aug 29, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Travere Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 4, 2012First study: phase 2 study in Glomerulosclerosis, Focal SegmentalFirst studyNCT01613118 · 109 enrolled · United States, Czechia, Italy
  2. Jun 9, 2015Named sparsentanINNProposed as its International Nonproprietary Name in WHO's List 113 · before, PS433540
  3. Apr 3, 2018Phase 3 study in Glomerulosclerosis, Focal SegmentalNCT03493685 · 371 enrolled · United States, Argentina, Australia and more
  4. Nov 27, 2018Phase 3 study in Glomerulonephritis, IGANCT03762850 · 406 enrolled · United States, Australia, Belgium and more
  5. Jul 29, 2021Phase 2 study in Glomerulosclerosis, Focal SegmentalNCT05003986 · 67 planned · United States, Germany, Italy and more
  6. Aug 23, 2022Phase 1 study in Glomerulosclerosis, Focal SegmentalNCT05562362 · 47 enrolled · United Kingdom
  7. May 3, 2023Phase 2 study in Glomerulonephritis, IGANCT05856760 · 48 enrolled · United States, Hong Kong
  8. Oct 9, 2025Phase 4 study in ProteinuriaNCT07219121 · 20 enrolled · United States

Ahead

  1. Mar 2027Primary completion: phase 4 study in ProteinuriaNCT07219121
  2. Mar 12, 2027Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalNCT05003986

TargetBeta

AGTR1 →EDNRA →read by rule
“Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Studies

All 7 Travere Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07219121Proteinuria · United States4Active, not recruitingMar 202720
NCT05856760Glomerulonephritis, IGA · United States, Hong Kong2CompletedOct 14, 202448
NCT05562362Glomerulosclerosis, Focal Segmental · United Kingdom1CompletedNov 12, 202047
NCT05003986Glomerulosclerosis, Focal Segmental · United States, Germany, Italy and more2RecruitingMar 12, 202767
NCT03762850Glomerulonephritis, IGA · United States, Australia, Belgium and more3CompletedAug 7, 2023406
NCT03493685Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more3CompletedMar 20, 2023371
NCT01613118Glomerulosclerosis, Focal Segmental · United States, Czechia, Italy2CompletedJun 2016109

How it is read

Names in the registry

  • “Sparsentan”, 5 entries
  • “PS433540”, 5 entries
  • “sparsentan”, 2 entries
  • “RE-021 (Sparsentan)”, 1 entry
  • “RE-021, sparsentan”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.